Skip to main content
Fig. 2 | Journal for ImmunoTherapy of Cancer

Fig. 2

From: Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade

Fig. 2

Galunisertib monotherapy induces regression of immunogenic 4T1-LP variant breast tumors. Mean and individual tumor growth curves for Balb/c mice injected orthotopically in the mammary fat pad with 4T1-LP (a) or parental 4T1 (b) tumor cells and treated with galunisertib (75 mg/kg BID) when tumors reached ~300mm3 (6–8 days after implantation). The number of mice/group rejecting tumors (complete responders, CRs) was: control (0/10 mice) and galunisertib (4/12) for 4T1-LP, and control (0/10 mice) and galunisertib (0/12) for 4T1 parental as indicated. Data shown are representative of two independent experiments with 10–12 mice/group

Back to article page